Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D
Summary
A star-stud\xadded mix of ven\xadture cap\xadi\xadtal\xadists and sci\xaden\xadtists, backed by more than a bil\xadlion dol\xadlars, is launch\xading an am\xadbi\xadtious biotech that aims to rein\xadvent drug R&D us\xading ar\xadti\xadfi\xadcial in\xadtel\xadli\xadgence, the group ex\xadclu\xadsive\xadly told End\xadpoints News.The com\xadpa\xadny, Xaira Ther\xada\xadpeu\xadtics, is one of this years most rich\xadly fund\xaded new com\xadpa\xadnies, not on\xadly in biotech but across the start\xadup world, re\xadflect\xading the en\xadthu\xadsi\xadasm and tech\xadno\xadlog\xadi\xadcal progress in us\xading AI to un\xadlock the mys\xadter\xadies of bi\xadol\xado\xadgy. The group has tapped Marc Tessier-Lav\xadi\xadgne, for\xadmer\xadly the pres\xadi\xaddent of Stan\xadford Uni\xadver\xadsi\xadty and chief sci\xaden\xadtif\xadic of\xadfi\xadcer of Genen\xadtech, as CEO to turn a cash-flush vi\xadsion in\xadto re\xadal\xadi\xadty.Unlock this article instantly by becoming a free subscriber. Youll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.